United Services Automobile Association lessened its stake in shares of GENFIT S A/ADR (NASDAQ:GNFT) by 5.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,050 shares of the company’s stock after selling 2,300 shares during the quarter. United Services Automobile Association owned about 0.11% of GENFIT S A/ADR worth $791,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in GNFT. Boussard & Gavaudan Investment Management LLP bought a new position in shares of GENFIT S A/ADR during the 2nd quarter worth about $199,000. Morgan Stanley boosted its position in shares of GENFIT S A/ADR by 24.4% during the 2nd quarter. Morgan Stanley now owns 10,700 shares of the company’s stock worth $211,000 after purchasing an additional 2,100 shares in the last quarter. One68 Global Capital LLC bought a new position in shares of GENFIT S A/ADR during the 1st quarter worth about $270,000. Balyasny Asset Management LLC bought a new position in shares of GENFIT S A/ADR during the 2nd quarter worth about $699,000. Finally, Bank of America Corp DE bought a new position in shares of GENFIT S A/ADR during the 2nd quarter worth about $889,000. 10.19% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on the stock. HC Wainwright set a $72.00 price objective on shares of GENFIT S A/ADR and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Stifel Nicolaus assumed coverage on shares of GENFIT S A/ADR in a research report on Tuesday, June 25th. They set a “hold” rating on the stock. Zacks Investment Research cut shares of GENFIT S A/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Finally, ValuEngine cut shares of GENFIT S A/ADR from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $45.69.
Shares of NASDAQ GNFT opened at $14.00 on Friday. GENFIT S A/ADR has a fifty-two week low of $13.21 and a fifty-two week high of $26.25. The company has a current ratio of 6.45, a quick ratio of 6.44 and a debt-to-equity ratio of 1.85. The company has a 50-day simple moving average of $16.42.
GENFIT S A/ADR Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Recommended Story: Liquidity
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.